Spinal muscular atrophy

Ionis to hold second quarter 2021 financial results webcast

Wednesday, July 21, 2021 - 12:05pm

CARLSBAD, Calif., July 21, 2021 /PRNewswire/ --Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, August 4th at 11:30 a.m. Eastern Time to discuss its second quarter 2021 financial results and report on pipeline and business progress.

Key Points: 
  • CARLSBAD, Calif., July 21, 2021 /PRNewswire/ --Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, August 4th at 11:30 a.m. Eastern Time to discuss its second quarter 2021 financial results and report on pipeline and business progress.
  • A webcast replay will be available for a limited time at the same address.
  • For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology.
  • Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry leading neurological and cardiometabolic franchises.

Eisai to Present Latest Data on Pipeline Assets in The Area of Alzheimer's Disease and Dementia at AAIC 2021

Wednesday, July 21, 2021 - 2:34am
Key Points: 
  • A poster presentation will also be given on the results of an in vivo study of E2511, Eisai's in-house discovered and developed investigational novel oral synapse regenerant.
  • Additionally, Eisai and Biogen Inc. (Nasdaq: BIIB) will hold a virtual symposium, "Defining the next-generation clinical care pathway for Alzheimer's disease: biological, technological, and healthcare perspectives," focusing on the AD treatment landscape.
  • Eisai serves as the lead in the co-development of lecanemab, an anti-Aβ protofibril antibody, which is being jointly developed by Eisai and Biogen.
  • Eisai aims to realize the prevention and cure of dementia through a multi-dimensional and holistic approach with a foundation of over 35 years of experience of drug discovery activities in the area of AD and dementia.

Entasis Therapeutics Expands Executive Leadership Team with the Appointment of Anna Diaz Triola as Chief Commercial Officer

Wednesday, July 14, 2021 - 1:00pm

WALTHAM, Mass., July 14, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today the appointment of Anna Diaz Triola as Chief Commercial Officer, effective July 19th 2021.

Key Points: 
  • WALTHAM, Mass., July 14, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today the appointment of Anna Diaz Triola as Chief Commercial Officer, effective July 19th 2021.
  • Ms. Triola will be responsible for global commercial strategy, including U.S. sales and marketing operations.
  • Anna brings a distinctive set of commercial and leadership skills to Entasis, and a track record of commercializing products across multiple therapeutic areas, including antibacterials.
  • Prior to joining Summit, Ms. Triola held commercial leadership roles at Flexion Therapeutics, Chiasma, Cubist, and Biogen.

Initial Launch Execution Fails to Impress for Biogen's Aduhelm - the First-to-Market Disease-Modifying Therapy for the Treatment of Alzheimer's Disease - as the Controversy Churn Continues, According to Spherix Global Insights

Wednesday, July 14, 2021 - 12:45pm

Spherix initiated their Launch Dynamix: Aduhelm (Biogen) in Alzheimer's Disease (US) service immediately upon approval to provide clients with an ongoing, real-time assessment of the brand's launch and to capture vital benchmarking for potential future launches.

Key Points: 
  • Spherix initiated their Launch Dynamix: Aduhelm (Biogen) in Alzheimer's Disease (US) service immediately upon approval to provide clients with an ongoing, real-time assessment of the brand's launch and to capture vital benchmarking for potential future launches.
  • Surveyed neurologists anticipate that only one in seven Alzheimer's patients are considered candidates for Aduhelm.
  • Biogen, considered a powerhouse in the multiple sclerosis market, has not yet fueled comparable loyalty in the Alzheimer's market.
  • All company, brand or product names in this document are trademarks of their respective holders.

Bicycle Therapeutics Enters Exclusive License and Collaboration Agreement with Ionis to Develop Targeted Oligonucleotide Therapeutics

Tuesday, July 13, 2021 - 11:59am

Ionis had an option for an exclusive license under the terms of a December 2020 evaluation and option agreement.

Key Points: 
  • Ionis had an option for an exclusive license under the terms of a December 2020 evaluation and option agreement.
  • Bicycle receives a total of $45 million upfront, which includes a license fee, an option fee, and an $11 million equity investment.
  • Bicycle is also eligible to receive development, regulatory and commercial milestone payments and royalties for each program developed under the collaboration.
  • This agreement stems from a highly successful collaboration with Ionis that began earlier in the year, during which Bicycles were shown to selectively deliver oligonucleotide payloads into TfR1-expressing tissue, said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics.

Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology

Tuesday, July 13, 2021 - 11:59am

CARLSBAD, Calif., July 13, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)today announced that it has entered into an exclusive licensing agreement with Bicycle Therapeutics plc (NASDAQ: BCYC) to increase the delivery capabilities of Ionis' advanced LIgand Conjugated Antisense (LICA) medicines.

Key Points: 
  • CARLSBAD, Calif., July 13, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)today announced that it has entered into an exclusive licensing agreement with Bicycle Therapeutics plc (NASDAQ: BCYC) to increase the delivery capabilities of Ionis' advanced LIgand Conjugated Antisense (LICA) medicines.
  • The agreement provides Ionis exclusive access to Bicycle's proprietary macrocyclic peptides, referred to as Bicycles, to design LICAs that target transferrin receptor 1 for use with oligonucleotides.
  • Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines, Bicycles, for diseases that are underserved by existing therapeutics.
  • In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" refers to Ionis Pharmaceuticals and its subsidiaries.

Collaboration Between AbbVie, Biogen and Pfizer Creates World’s Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health and Disease

Thursday, July 8, 2021 - 9:06pm

and NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- Today, access to the worlds largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between AbbVie (NYSE: ABBV), Biogen Inc.(Nasdaq: BIIB) and Pfizer (NYSE: PFE).

Key Points: 
  • and NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- Today, access to the worlds largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between AbbVie (NYSE: ABBV), Biogen Inc.(Nasdaq: BIIB) and Pfizer (NYSE: PFE).
  • These genetic data have been paired with detailed health information to create this browsable resource.
  • The collaboration between AbbVie, Biogen and Pfizer to make these data available highlights the importance of working together to advance science.
  • In line with the collaboration members commitment to openness, these results can now be accessed freely via the new browser.

Catalyst Biosciences to Host Research and Development Day on CB 4332 and Complement Programs

Thursday, July 1, 2021 - 1:00pm

Catalysts complement portfolio is led by the development candidates CB 4332 and CB 2782-PEG, originating from the companys internal discovery platform, which has generated a rich pipeline of leads.

Key Points: 
  • Catalysts complement portfolio is led by the development candidates CB 4332 and CB 2782-PEG, originating from the companys internal discovery platform, which has generated a rich pipeline of leads.
  • CB 4332 is an engineered CFI protease with the potential to become a therapy addressing multiple complement related disorders.
  • CB 2782-PEG is a potential best-in-class C3 degrader product candidate in preclinical development for the treatment of dry AMD that Catalyst has licensed to Biogen.
  • Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems.

Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ™

Friday, June 25, 2021 - 12:30pm

The CHMPs positive opinion will now be referred to the European Commission (EC), which will decide whether to grant a marketing authorization for BYOOVIZ.

Key Points: 
  • The CHMPs positive opinion will now be referred to the European Commission (EC), which will decide whether to grant a marketing authorization for BYOOVIZ.
  • We are very proud to see BYOOVIZ becoming the first biosimilar of ranibizumab to be recommended for approval in Europe.
  • This positive CHMP opinion on BYOOVIZ was based on a Phase 3 clinical study that demonstrated equivalence in efficacy for both primary endpoints.
  • Samsung Bioepis is a joint venture between Samsung Biologics and Biogen.

Eisai and Biogen Inc. Announce U.S. FDA Grants Breakthough Therapy Designation for Lecanemab (BAN2401)

Thursday, June 24, 2021 - 4:00am

TOKYO, June 24, 2021 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthough Therapy designation for lecanemab (BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of Alzheimer's disease (AD).

Key Points: 
  • TOKYO, June 24, 2021 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthough Therapy designation for lecanemab (BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of Alzheimer's disease (AD).
  • Breakthrough Therapy designation is an FDA program intended to expedite the development and review of medicines for serious or life-threatening conditions.
  • The benefits of a Breakthrough Therapy designation include more intensive guidance on an efficient development program as well as eligibility for rolling review and potentially priority review.
  • In March 2021 Eisai and Biogen completed enrollment of 1,795 patients with early AD in the the Phase 3 Clarity AD study.